Despite concerns about the efficacy and safety of checkpoint inhibitors, many biotech companies are advancing them in clinical trials to treat cancer. By 2032, the market for these drugs could reach nearly $189.4 billion. While these inhibitors have shown dramatic results in some cancer patients, they only seem to work for a small percentage. As a result, research is shifting towards combining them with other cancer treatments, and exploring potential new inhibitors. These advances are expected to revolutionize cancer care.
Dragos unveils OT-native AI to help critical infrastructure teams prioritize threats faster
Dragos has announced the release of EmberAI, an OT-native AI built on the Dragos Intelligence Fabric. EmberAI gives every analyst immediate access to Dragos’s OT-specific
